Key result
A 70-year-old woman with asthma developed takotsubo cardiomyopathy triggered by asthma exacerbation 12 hours after receiving the second dose of the BNT162b2 COVID-19 vaccine.
Case Report (n=1)
No
This case report suggests that mRNA-based COVID-19 vaccination may trigger asthma exacerbations leading to takotsubo cardiomyopathy, highlighting the need for risk stratification in patients with asthma.
Answers are grounded in this paper and cite their sources.
Warrants vigilance for respiratory complications post-vaccination in severe asthma; hypothesis-generating for mRNA-triggered takotsubo cardiomyopathy.
It is recommended to get the multiple coronavirus disease 2019 (COVID-19) vaccinations for almost all people including asthma patients. A 70-year-old Japanese woman with asthma experienced worsening of respiratory symptoms after the second dose of the mRNA-based COVID-19 vaccine BNT162b2. The patient had hypercapnic respiratory failure and cardiac-apex ballooning and was diagnosed with takotsubo cardiomyopathy induced by asthma exacerbation. Therapies for asthma exacerbation resulted in prompt improvement of respiratory failure and cardiac-apex ballooning. Our findings suggest that asthma patients are prone to exacerbations after receiving the COVID-19 vaccination; therefore, stratification of the patients at risk is required.
No takes yet. Share an insight, caveat, or question.
Tachibana et al. (2023) conducted a case report in Takotsubo cardiomyopathy and asthma exacerbation (n=1). mRNA-based COVID-19 vaccine BNT162b2 was evaluated. A 70-year-old woman with asthma developed takotsubo cardiomyopathy triggered by asthma exacerbation 12 hours after receiving the second dose of the BNT162b2 COVID-19 vaccine.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: